We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine
November 5, 2013
U.S.-based biopharmaceutical company Nanotherapeutics has started enrollment of first patient in a Phase II cervical cancer trial for Triapine, a ribonucleotidereductase inhibitor. Pharmaceutical Business Review
